News | April 09, 2009

Novel Stent Designed to Aid Heart Attack Patients Needs Further Study

April 9, 2009 - Researchers say a larger trial is needed to effectively test a novel stent designed to speed arterial healing in heart attack patients by attracting the body’s own circulating stem cells to create a protective layer over the implanted device.

Research from the Randomized Comparison of Genous Stent Versus Chromium-Cobalt Stent for Treatment of ST-Elevation Myocardial Infarction (GENIUS-STEMI) trial was presented during the i2 Summit the ACC’s 58th annual scientific session last week in Orlando, FL.

In the trial, researchers evaluated the investigational stent’s ability to reduce both restenosis of the treated artery and blood clot formation on the stent (stent thrombosis). Instead, the study demonstrated increased rates of both, when compared to a third-generation bare-metal stent.

“The results have to be interpreted cautiously because this is a small, single-center study,” said Pavel Cervinka, M.D., Ph.D, an associate professor and head of cardiology at Masaryk Hospital and University of J.E. Purkyne, Ústí nad Labem, Czech Republic. “However, in a head-to-head comparison, the chromium-cobalt stents were doing better than the Genous stent at six month follow-up.”

For the GENIUS-STEMI study, 100 consecutive patients with ST-elevation myocardial infarction (STEMI) were studied. Equal numbers of patients were randomly assigned to undergo stenting with the Genous EPC (endothelial progenitor cells) capture stent or a chromium-cobalt stent.

The Genous stent is designed to reduce the risk of restenosis while overcoming the tendency toward late stent thrombosis that has shadowed drug-eluting stents. Coated with an antibody, the Genous stent attracts circulating EPCs. These EPCs are naturally elevated in response to arterial injury and have the capacity to differentiate into mature endothelial cells, like those lining the inner surface of arteries. It is hoped that this unique characteristic will accelerate the healing process, protect against blood clot formation, and minimize restenosis in stented arteries. Previous data from non-randomized studies and clinical registries have been promising.

During follow-up, researchers evaluated the patients clinically as well as with angiographic imaging and intravascular ultrasound. They found that at 30 days, the combined rate of major adverse cardiac events (MACE)—defined as heart attack, cardiovascular death, and repeat treatment of the target lesion—was comparable in the two groups. At six months, however, there was a significantly higher MACE rate among patients treated with the Genous stent when compared with those treated with the chromium-cobalt stent (24 percent vs.10 percent; p=0.03). Patients treated with the Genous stent also had a statistically higher rate of repeat procedures in the originally targeted lesion (14 percent vs. 4 percent; p=0.04).

Intravascular ultrasound showed larger amounts of tissue overgrowth, the most common cause of restenosis, inside the Genous stent, although the difference was not statistically significant. In addition, there were three cases of late stent thrombosis in patients treated with the Genous stent (6 percent), but none in patients treated with the chromium-cobalt stent.

The researchers concluded that use of the Genous EPC capture stent in patients suffering from an acute heart attack is feasible and safe, while expressing caution over the unfavorable results compared to the chromium-cobalt stent.

“The rate of late stent thrombosis in the Genous group is worrisome,” Dr. Cervinka said. “Before generalizing these results, a large randomized trial is needed to finally address this issue.”

For information: www.acc.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init